Healio

Phase 3 trial of canakinumab for lung cancer misses primary endpoints

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The addition of canakinumab to pembrolizumab and ...
Nasdaq

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous ...
Healio

Phase 3 trial of canakinumab for non-small cell lung cancer misses endpoint

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A randomized phase 3 trial designed to evaluate ...
FiercePharma

AACR: Novartis aims to keep canakinumab's early lung cancer hopes alive despite metastatic failure

When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said supported continued exploration of the med in ...
Nasdaq

Novartis: Phase III CANOPY-A Study Evaluating Canakinumab Fails To Meet Primary Goal

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885) did not meet its primary endpoint of ...
FiercePharma

Novartis' closely watched canakinumab hits a snag in lung cancer. What's next for the anti-inflammatory drug?

First it was heart disease, now it’s non-small cell lung cancer (NSCLC). Novartis can’t seem to make its canakinumab injection work outside immunology, where the drug’s currently sold as Ilaris. The ...
ascopubs.org

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018) In total, 1,382 patients were ...
ascopubs.org

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy Overall, 643 patients were ...
Bloomberg L.P.

Novartis’s Canakinumab Fails in Another Lung Cancer Trial

Novartis AG said a late-stage trial of experimental lung-cancer drug canakinumab failed, likely the last blow for a repurposed medicine that had already failed in one lung cancer study last year.